EDUCATIONAL NOTICE: Peptidings provides information for educational and research purposes only. The compounds in this research cluster are subjects of ongoing scientific investigation at varying stages of development. None of the information presented here constitutes medical advice or a recommendation for use. Consult a qualified healthcare provider before making any decisions about peptide use.
Research Cluster
Sleep, Stress & Recovery Peptides
Sleep peptides and the related neuropeptides of stress response and circadian biology span FDA-approved drugs used in clinical diagnostics to preclinical research compounds still being characterized in animal models.
Several compounds here carry WADA prohibitions, reflecting their potential to influence hormonal recovery and performance-relevant physiology.
Cluster at a Glance
|
9 Compounds Covered |
3 Approved Drug |
2 Clinical Trials |
1 Pilot / Limited Human Data |
3 Preclinical Only |
|
Approved Drug FDA-approved or equivalent regulatory approval |
Clinical Trials Human clinical trial data (Phase I+) |
Pilot / Limited Human Data Small or preliminary human studies |
Preclinical Only Animal models and cell culture only |
BLUF: Bottom Line Up Front
Three FDA-approved compounds (Cosyntropin, Desmopressin, Orexin/Suvorexant) anchor this cluster, but their approved indications are narrow—adrenal diagnostics, nocturnal enuresis, and insomnia, respectively. The clinical-stage compounds (Neuropeptide Y, PACAP) have fascinating neurobiology but incomplete therapeutic development. The preclinical compounds (Galanin, CRH, Cortistatin, MCH) represent important neuroscience targets that have not yet translated to drugs. This is a cluster where the biology is well-understood but the therapeutics are still catching up.
In This Article
Compounds in This Cluster
All 9 compounds in the Sleep, Stress & Recovery Peptides cluster, organized by mechanism and editorial function. Each grouping reflects how these compounds relate to each other scientifically—not just alphabetically.
Group 1 of 3
The Approved Neuroendocrine Drugs
FDA-approved peptides with established clinical roles in endocrine diagnostics, fluid balance, and sleep regulation.
Group 2 of 3
The Clinical Neuroscience Targets
Neuropeptides with substantial human research data but incomplete therapeutic development.
|
|
|
Group 3 of 3
The Preclinical Frontier
Research neuropeptides with well-characterized biology but no therapeutic development in humans.
|
|
|
How These Compounds Relate
The nine compounds in this cluster map onto the brain circuits that govern wakefulness, sleep architecture, and stress response. The orexin system is the master wakefulness switch—its pharmaceutical blockade produced the first mechanistically novel insomnia drugs in decades. Cosyntropin and CRH sit on opposite sides of the same stress axis: CRH initiates the cortisol cascade, while Cosyntropin (synthetic ACTH) tests whether the adrenal glands can respond to it.
Neuropeptide Y and PACAP represent the stress resilience pathway. NPY is associated with psychological hardiness—Special Forces soldiers with higher NPY levels show less stress-related impairment. PACAP is its counterpart in the migraine and circadian disruption space, with clinical data suggesting it may mediate the connection between stress and headache disorders.
The preclinical compounds (Galanin, Cortistatin, MCH) each regulate specific sleep stages. Cortistatin promotes slow-wave (deep) sleep, MCH promotes REM sleep, and Galanin modulates both through its role in the ventrolateral preoptic area. Desmopressin works through an entirely different mechanism—reducing overnight urine production—which improves sleep by preventing nocturia-related awakenings.
| Shared Mechanism | Compounds |
|
Orexin / Wakefulness Signaling Controls the on/off switch for wakefulness. Blockade promotes sleep onset and maintenance. |
Orexin |
|
HPA Stress Axis Regulates the cortisol stress response cascade from hypothalamic CRH through pituitary ACTH to adrenal cortisol. |
Cosyntropin, Corticotropin-Releasing Hormone |
|
Stress Resilience / Neuroprotection Modulates psychological stress response, anxiety, and resilience through distinct receptor systems. |
Neuropeptide Y, PACAP, Galanin |
|
Sleep Architecture Regulation Directly promotes specific sleep stages—slow-wave or REM—through hypothalamic circuits. |
Cortistatin, Melanin-Concentrating Hormone, Galanin |
Plain English
Your brain has specific peptide systems that control when you sleep, how deeply you sleep, and how you respond to stress. This cluster covers all of them. The orexin system is your wakefulness switch—blocking it is how the newest sleeping pills work. CRH and Cosyntropin control your cortisol stress response. NPY is the resilience peptide—people with more of it handle stress better. Three other peptides (Cortistatin, MCH, Galanin) fine-tune specific sleep stages in animal models but have not become drugs yet. And Desmopressin helps you sleep through the night by reducing bathroom trips. The approved drugs here are well-proven; the research compounds are well-characterized but still preclinical.
Stay Current
New research, new articles, no noise
Peptidings publishes long-form peptide research articles grounded in primary literature. Subscribe to get new compound articles, cluster updates, and evidence reviews delivered to your inbox.
Disclaimer: This page is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. The compounds discussed are subjects of ongoing scientific research and have not been evaluated by the FDA for all applications described. Consult a qualified healthcare provider before making any decisions about your health.